Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background And Aims: Data on the outcomes after switching from adalimumab (ADA) originator to ADA biosimilar are limited. The aim was to compare the treatment persistence, clinical efficacy, and safety outcomes in inflammatory bowel disease patients who maintained ADA originator vs. those who switched to ADA biosimilar.
Methods: Patients receiving ADA originator who were in clinical remission at standard dose of ADA originator were included. Patients who maintained ADA originator formed the non-switch cohort (NSC), and those who switched to different ADA biosimilars constituted the switch cohort (SC). Clinical remission was defined as a Harvey-Bradshaw index ≤4 in Crohn's disease and a partial Mayo score ≤2 in ulcerative colitis. To control possible confounding effects on treatment discontinuation, an inverse probability treatment weighted proportional hazard Cox regression was performed.
Results: Five hundred and twenty-four patients were included: 211 in the SC and 313 in the NSC. The median follow-up was 13 months in the SC and 24 months in the NSC (p < 0.001). The incidence rate of ADA discontinuation was 8% and 7% per patient-year in the SC and in the NSC, respectively (p > 0.05). In the multivariate analysis, switching from ADA originator to ADA biosimilar was not associated with therapy discontinuation. The incidence rate of relapse was 8% per patient-year in the SC and 6% per patient-year in the NSC (p > 0.05). Six percent of the patients had adverse events in the SC vs. 5% in the NSC (p > 0.05).
Conclusion: Switching to ADA biosimilar did not impair patients' outcomes in comparison with maintaining on the originator.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/apt.17525 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Medical Expert Knowledge Meets AI to Enhance Symptom Checker Performance for Rare Disease Identification in Fabry Disease: Mixed Methods Study.
JMIR AI
August 2025
Department of Nephrology and Hypertension, Hannover Medical School, Carl-Neuberg-Strasse 1, Hannover, 30625, Germany, 49 511 532 3745.
Background: Rare diseases, which affect millions of people worldwide, pose a major challenge, as it often takes years before an accurate diagnosis can be made. This delay results in substantial burdens for patients and health care systems, as misdiagnoses lead to inadequate treatment and increased costs. Artificial intelligence (AI)-powered symptom checkers (SCs) present an opportunity to flag rare diseases earlier in the diagnostic work-up.
View Article and Find Full Text PDFRole of Antidrug Antibodies in Oncolytic Viral Therapy: A Dynamic Modelling Approach in Cancer Patients Treated with V937 Alone or in Combination.
Clin Pharmacokinet
August 2025
Quantitative Pharmacology and Pharmacometrics Immune/Oncology (QP2-I/O), Merck & Co., Inc., Rahway, NJ, USA.
Background And Objective: Oncolytic viruses (OVs) are a growing immuno-oncology therapeutic class that rely on their capability to activate the dormant endogenous anti-tumor immune response in order to control or eradicate tumor cells. Given their intrinsic mechanisms of action and their biological nature, development of antidrug antibodies (ADA) represents an important aspect to consider during clinical evaluation. ADAs can potentially affect viral kinetics and/or dynamics, ultimately resulting in reductions or even loss of drug efficacy.
View Article and Find Full Text PDFPharmacokinetic Bioequivalence, Safety, and Immunogenicity of DMB-3115, an Ustekinumab Biosimilar, and EU- and US-Stelara in Healthy Adult Participants: A Randomized, Double-Blind, Single-Dose Study.
Adv Ther
September 2025
R&D Division, Meiji Seika Pharma Co., Ltd., 2-4-16, Kyobashi, Chuo-ku, Tokyo, 104-8002, Japan.
Introduction: The aim of this study was to investigate the pharmacokinetic bioequivalence between DMB-3115 and ustekinumab (EU-Stelara or US-Stelara) as well as the safety and immunogenicity of these drugs in healthy adult participants.
Methods: This was a randomized, double-blind, three-arm parallel-group study. Healthy participants aged 18-55 years were randomly assigned in a 1:1:1 ratio to receive a single subcutaneous injection (45 mg) of either DMB-3115, EU-Stelara, or US-Stelara.
Recognising, quantifying and accounting for classification uncertainty in type 2 diabetes subtypes.
Diabetologia
July 2025
Institute for Biometrics and Epidemiology, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
Aims/hypothesis: Despite continued interest in precision diagnostics and type 2 diabetes subtypes, the challenge of uncertainty in the classification of individuals into subtypes remains. This study introduces a novel method for quantifying and accounting for classification uncertainty in type 2 diabetes subtypes.
Methods: Building on recommendations from the ADA/EASD Precision Medicine in Diabetes Initiative, we quantified classification uncertainty using the normalised relative entropy (NRE), computed from distances to cluster centroids.
Dual-targeted therapy for the management of refractory Crohn's disease: a retrospective cohort study.
Clin Exp Med
July 2025
Xijing Hospital of Digestive Diseases, State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers and National Clinical Research Center for Digestive Diseases, Fourth Military Medical University, 127 Changle West Road, Xi'an, China.
Crohn's disease (CD) is a chronic relapsing autoimmune disease. Dual-targeted therapy (DTT) has been proven effective and safe in refractory inflammatory bowel disease (IBD), especially the combination of ustekinumab with vedolizumab (UST + VDZ). However, the efficacy and safety of DTT on refractory CD are still limited or insufficient.
View Article and Find Full Text PDF